BRAIN Biotech AG (ETR:BNN)
Germany · Delayed Price · Currency is EUR 2.340
-0.020 (-0.85%)
Mar 6, 2026, 5:35 PM CET
BRAIN Biotech AG Income Statement
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Revenue | 49.01 | 50.22 | 55.5 | 56.23 | 50.3 | 39.22 |
Other Revenue | 0 | - | 0 | - | - | - |
| 49.01 | 50.22 | 55.5 | 56.23 | 50.3 | 39.22 | |
Revenue Growth (YoY) | -12.20% | -9.52% | -1.29% | 11.79% | 28.23% | 0.40% |
Cost of Revenue | 20.75 | 22.12 | 24.94 | 25.8 | 22.69 | 17.4 |
Gross Profit | 28.26 | 28.1 | 30.56 | 30.42 | 27.61 | 21.82 |
Selling, General & Admin | 22.26 | 22.57 | 26.36 | 23.34 | 23.06 | 20.5 |
Other Operating Expenses | 7.85 | 8.16 | 8.39 | 7.99 | 6.59 | 4.69 |
Operating Expenses | 35.23 | 35.85 | 39.58 | 35.98 | 33.99 | 29.21 |
Operating Income | -6.97 | -7.76 | -9.01 | -5.56 | -6.38 | -7.39 |
Interest Expense | -2.38 | -2.21 | -1.94 | -0.86 | -0.53 | -0.52 |
Interest & Investment Income | - | - | - | - | 0 | 0.01 |
Earnings From Equity Investments | -0.49 | -0.53 | -0.5 | -1.49 | -2.43 | -1.72 |
Currency Exchange Gain (Loss) | 0.21 | 0.21 | -0.11 | -0.06 | 0.12 | -0.04 |
Other Non Operating Income (Expenses) | -1.61 | -2.02 | 0.52 | 0.09 | 0.28 | 3.98 |
EBT Excluding Unusual Items | -11.24 | -12.3 | -11.04 | -7.89 | -8.93 | -5.68 |
Merger & Restructuring Charges | - | - | - | -0.28 | -0.48 | -0.31 |
Gain (Loss) on Sale of Investments | - | - | - | 0.54 | 2.36 | 0.58 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.65 | - |
Other Unusual Items | 0.27 | 0.27 | 0.05 | 0.13 | 0.24 | 1.14 |
Pretax Income | -10.97 | -12.02 | -10.99 | -7.49 | -6.17 | -4.28 |
Income Tax Expense | -0.26 | -0.19 | 0.11 | 0.63 | 0.18 | 0.4 |
Earnings From Continuing Operations | -10.71 | -11.83 | -11.1 | -8.11 | -6.34 | -4.68 |
Minority Interest in Earnings | 0.09 | 0.09 | -0.03 | -0.17 | -0.25 | -0.29 |
Net Income | -10.62 | -11.74 | -11.13 | -8.28 | -6.59 | -4.97 |
Net Income to Common | -10.62 | -11.74 | -11.13 | -8.28 | -6.59 | -4.97 |
Shares Outstanding (Basic) | 22 | 22 | 22 | 22 | 22 | 20 |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 22 | 22 | 20 |
Shares Change (YoY) | - | - | - | - | 9.55% | 6.89% |
EPS (Basic) | -0.49 | -0.54 | -0.51 | -0.38 | -0.30 | -0.25 |
EPS (Diluted) | -0.49 | -0.54 | -0.51 | -0.38 | -0.30 | -0.25 |
Free Cash Flow | -9.49 | -10.77 | -5.14 | -6.84 | -7.29 | -5.16 |
Free Cash Flow Per Share | -0.43 | -0.49 | -0.23 | -0.31 | -0.33 | -0.26 |
Gross Margin | 57.66% | 55.95% | 55.07% | 54.11% | 54.89% | 55.63% |
Operating Margin | -14.21% | -15.45% | -16.24% | -9.89% | -12.69% | -18.84% |
Profit Margin | -21.67% | -23.38% | -20.05% | -14.72% | -13.10% | -12.68% |
Free Cash Flow Margin | -19.36% | -21.44% | -9.25% | -12.16% | -14.49% | -13.15% |
EBITDA | -3.57 | -4.35 | -5.73 | -2.39 | -3.27 | -4.1 |
EBITDA Margin | -7.29% | -8.67% | -10.32% | -4.25% | -6.51% | -10.45% |
D&A For EBITDA | 3.4 | 3.4 | 3.29 | 3.18 | 3.11 | 3.29 |
EBIT | -6.97 | -7.76 | -9.01 | -5.56 | -6.38 | -7.39 |
EBIT Margin | -14.21% | -15.45% | -16.24% | -9.89% | -12.69% | -18.84% |
Revenue as Reported | 51.83 | 51.59 | 55.52 | 57.14 | 53.07 | 40.73 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.